Sydney Jennings

New research shows 35.3% of insured individuals with hypertensive disorders of pregnancy had a preventive care visit within 12 months postpartum.

ECHO-based menopause education improved PCP confidence and revealed gaps in sexual health, bleeding, and weight management training, according to new research.

Details on 11 key abstracts with clinical relevance for primary care, from menopause management to cervical cancer screening.

ACP Internal Medicine Meeting 2026 highlights: new mammography guidelines, AI scribe limitations, and muscle loss risks with GLP-1 weight loss drugs.

WHO’s 2025 kidney health resolution pushes nations to spot CKD earlier, bolster primary care treatment, and expand dialysis and transplant access.

Phase 3 data show IL‑33 antibody tozorakimab cuts COPD flare-ups across smokers and low eosinophils, hinting a new biologic option.

The TRIDENT trial shows a once-daily triple BP pill after intracerebral hemorrhage improves control and lowers recurrent stroke and cardiovascular events.

FDA approves doravirine/islatravir for adults with virologically suppressed HIV-1, offering a once-daily 2-drug regimen with noninferior efficacy.

Steven Nissen, MD, discusses new SURPASS-CVOT data showing reduced cardiorenal events and mortality with tirzepatide vs dulaglutide.

A new executive order aims to speed up FDA access to psychedelic therapies; psychiatrist Gus Alva, MD, reviews evidence, safety risks, and more.

Test your knowledge of 2024 CDC STI data on high-risk populations and what it means for your screening decisions.

Test your knowledge of 2024 syphilis trends, staging distribution, and declines in primary and secondary disease.

Phase 3 CORALreef AddOn shows oral PCSK9 inhibitor enlicitide cuts LDL 65% on statins, potentially easing primary care lipid control.

Highlights include once-weekly insulin, obesity therapies, and new options for psoriasis and rare diseases.

Try your hand at these 5 questions on the latest US CDC STI data.

Women with diabetes receive less contraception, cancer screening, and preconception care, increasing risk for preventable complications.

Study of 669 083 patients links antidepressants and some antidiarrheals to higher mortality in IBS, raising prescribing concerns.

Phase 3 data show an investigational 6-valent OspA-based Lyme vaccine prevents more than 70% of cases; regulatory submissions planned.

New AHA/ASA stroke guidance widens thrombolysis and EVT access, eases imaging, and updates BP/glucose targets—what frontline teams need now.

The algorithm adds a new diabetes classification pathway and expands comorbidity-driven pharmacotherapy guidance, incorporating recent trial data on GLP-1 receptor agonists, SGLT2 inhibitors, and MASLD.

Phase 3 data show oral PCSK9 inhibitor enlicitide reduced LDL-C by 64.6% at 8 weeks vs oral nonstatins in high-risk patients.

Phase 3b findings suggest that combining a GLP-1/GIP receptor agonist with IL-17 inhibition may improve both joint and metabolic outcomes in adults with psoriatic arthritis and obesity.

Your daily dose of the clinical news you may have missed.

The approval of Foundayo (orforglipron) marks a formulation milestone in obesity pharmacotherapy, offering a once-daily pill free of the fasting requirements that may complicate adherence.

From new oral options for for psoriatic disease to once-weekly insulin, 5 FDA decisions with implications for primary care practice.

Your daily dose of the clinical news you may have missed.

Test your knowledge of added sugar limits, processed food reduction, and label interpretation in the 2025–2030 Dietary Guidelines.

ACC 2026. Evolocumab reduced first CV events by 31% in high-risk diabetes without ASCVD, supporting earlier LDL-C intensification.

Your daily dose of the clinical news you may have missed.

From oral GLP-1s for obesity and T2D to a potential first new smoking cessation drug in 20 years, here are 5 FDA pipeline updates to put on your radar.